Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Exicure ( (XCUR) ) has provided an update.
Exicure, Inc. announced that its shareholders approved an $8.7 million equity financing from HiTron Systems Inc., which will lead to HiTron becoming the company’s largest shareholder, owning over 50% of the company. This transaction, along with a prior investment, is expected to help Exicure regain compliance with Nasdaq’s equity requirements, allowing the company to focus on its core pipeline and strategic pursuits, including discussions with a US therapeutics company.
More about Exicure
Exicure, Inc. is an early-stage biotechnology company that has focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following a recent restructuring, the company has suspended its clinical and development activities and is exploring strategic alternatives to maximize stockholder value, considering both its historical biotechnology assets and broader opportunities.
YTD Price Performance: 442.76%
Average Trading Volume: 747,399
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $41.01M
For an in-depth examination of XCUR stock, go to TipRanks’ Stock Analysis page.
